Axcella Addresses Metabolic Disease Quickly With GRAS Candidates

Non-IND Development Pathway May Save Time And Money

Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.

Emerging Company Profile Regular column feature image Version 2

Like many companies, Axcella Health Inc. is a biotech that diverted from its original business plan after learning more about the strengths and weaknesses of its platforms. It began life in 2011 as Pronutria Inc., seeking to bring high-quality proteins to a broad customer base, but shifted focus about three years ago to develop drugs for metabolic and other diseases from finely tuned combinations of amino acids.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Start-Ups & SMEs

Veraxa Takes SPAC Route To Develop Bispecific ADCs and T-Cell Engagers

 

The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By 

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

 

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.

Glycomine Funds Phase IIb Rare Disease Trial With $115m Series C

 
• By 

Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.

More from Business

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By 

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.